Projectes destacats

  • Deciphering the life histories of chronic lymphocytic leukemia to improve clinical outcome (CLL-STORY)

    Investigador/a principal: Ferran Nadeu Prat.
    Finançador: European Research Council (ERC).
    Codi: 101222226.
    Durada: 01/01/2026 - 31/12/2030
  • Contrato Miguel Servet 2025

    Investigador/a principal: Ferran Nadeu Prat.
    Finançador: Instituto de Salud Carlos III.
    Codi: CP25/00084.
    Durada: 01/01/2026 - 31/12/2030
  • Caracterización de la evolución clonal y las interacciones del microambiente que dictan la progresión de la leucemia linfocítica crónica y la transformación de Richter

    Investigador/a principal: Ferran Nadeu Prat.
    Finançador: Fundacion Espanola de Hematologia y Hemoterapia (FEHH).
    Codi: FEHH_BECAS24_01.
    Durada: 01/01/2025 - 31/12/2025
  • Genomic and transcriptomic diversification driving resistance to CAR-T cell therapy in mantle cell lymphoma

    Investigador/a principal: Ferran Nadeu Prat.
    Finançador: Gilead.
    Codi: GLD23_00086.
    Durada: 30/01/2024 - 29/01/2026
  • Tracking the origin of chronic lymphocytic leukemia progression and transformation through its genomic and transcriptomic footprints

    Investigador/a principal: Ferran Nadeu Prat.
    Finançador: European Hematology Association (EHA).
    Codi: EHA Junior Research Grant 2021 (RG-202012-00245).
    Durada: 01/01/2022 - 31/12/2024
  • Tracking the origin of chronic lymphocytic leukemia progression and transformation through its genomic and transcriptomic footprints

    Investigador/a principal: Ferran Nadeu Prat.
    Finançador: Lady Tata Memorial Trust.
    Codi: International Award for Research in Leukaemia 2021-2022 (LADY_TATA_21_3223).
    Durada: 01/10/2021 - 30/09/2022
  • Tracking the progression and transformation of chronic lymphocytic leukemia

    Investigador/a principal: Ferran Nadeu Prat.
    Finançador: American Association for Cancer Research (AACR).
    Codi: American Association for Cancer Research (AACR)-Amgen Fellowship in Clinical/Translational Cancer Research (21-40-11-NADE).
    Durada: 01/07/2021 - 30/06/2023